New therapies including CAR-T, bispecific antibodies and dual-antibody immunotherapy are reshaping multiple myeloma care. Advances in genomic testing may also improve risk assessment and treatment decisions.
The global antibody drug conjugate market is calculated at USD 14.76 billion in 2026 and is expected to reach USD 32.66 billion by 2035. North America held a 53% share in 2025, while Asia Pacific is projected to grow fastest.
Calls are growing to bring CAR-T cell therapy to New Zealand as the current trial is set to end later this year. There is no clear path to public availability.
The University of Cincinnati Cancer Center’s Blood Cancer Healing Center added research laboratories and the UC Osher Wellness Suite and Learning Kitchen. The expansion joins clinical services launched in July 2024 and adds new research, wellness and community programming space.
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
Researchers used cryo-EM/ET imaging to analyze the HTLV capsid protein structure, revealing insights into virus assembly and potential therapeutic targets for adult T-cell leukemia/lymphoma. The study identified how the virus is assembled and reproduced, with findings that could inform drug design similar to HIV treatments. This research addresses a critical need as there are currently no approved therapeutics for HTLV infection.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07305090 |
Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut |
RECRUITING | |
| NCT07148180 |
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax |
RECRUITING | PHASE1/PHASE2 |
| NCT07052916 |
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties |
RECRUITING | NA |
| NCT06904066 |
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies |
RECRUITING | PHASE1 |
| NCT06817759 |
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer |
NOT_YET_RECRUITING | NA |
| NCT06645132 |
Understanding the Implementation of Cued Exercise Using Wearable Devices and a Custom Smartphone Application Following Bone Marrow Transplant. |
ACTIVE_NOT_RECRUITING | NA |
| NCT06582849 |
Enhanced Assistance During Radiotherapy for Unmet Essential Needs |
COMPLETED | NA |
| NCT06574308 |
Clinical Evaluation of the Scopio Cell Morphology Technology |
NOT_YET_RECRUITING | |
| NCT06543511 |
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies |
WITHDRAWN | NA |
| NCT06510699 |
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial |
RECRUITING | PHASE2 |
